Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Armata Pharmaceuticals, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +2 vs. Q4 2024
- Shares held
- 741.8K
- −648.5K (−46.6%) vs. Q4 2024
- Total value
- $1.08M
- −$1.49M (−57.9%) vs. Q4 2024
- New holders
- 2
- 2 more added
- Sold out
- 0
- 9 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARMP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 53 | $32.3M |
| Q1 2026 | 45 | $40.2M |
| Q4 2025 | 36 | $7.85M |
| Q3 2025 | 28 | $2.27M |
| Q2 2025 | 29 | $1.40M |
| Q1 2025 | 26 | $1.08M |
| Q4 2024 | 24 | $2.57M |
| Q3 2024 | 24 | $3.28M |
| Q2 2024 | 23 | $3.86M |
| Q1 2024 | 24 | $5.93M |
| Q4 2023 | 25 | $4.17M |
| Q3 2023 | 23 | $3.85M |
| Q2 2023 | 22 | $1.35M |
| Q1 2023 | 23 | $2.06M |
| Q4 2022 | 26 | $1.61M |
| Q3 2022 | 20 | $5.73M |
| Q2 2022 | 19 | $5.25M |
| Q1 2022 | 20 | $6.61M |
| Q4 2021 | 17 | $7.25M |
| Q3 2021 | 20 | $4.32M |
| Q2 2021 | 21 | $4.59M |
| Q1 2021 | 23 | $5.62M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Armata Pharmaceuticals, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 260,073 | $379.7K | 0.00% | +25,954+11.1% | Added |
| Geode Capital Management, LLC | 105,837 | $154.6K | 0.00% | −952−0.9% | Reduced |
| Edgewood Management LLC | 100,000 | $146.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 44,682 | $65.2K | 0.00% | −25,000−35.9% | Reduced |
| State Street Corp | 40,300 | $58.8K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 38,596 | $56.4K | 0.00% | −1,695−4.2% | Reduced |
| SeaCrest Wealth Management, LLC | 34,954 | $51.0K | 0.01% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 27,681 | $40.4K | 0.00% | −22,107−44.4% | Reduced |
| BlackRock, Inc. | 23,184 | $33.8K | 0.00% | −441−1.9% | Reduced |
| Citadel Advisors LLC | 20,594 | $30.1K | 0.00% | +20,594 | New |
| Northern Trust Corp | 19,273 | $28.1K | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 13,140 | $19.2K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 4,798 | $7.00K | 0.00% | −6,816−58.7% | Reduced |
| Tower Research Capital LLC (TRC) | 3,471 | $5.07K | 0.00% | +159+4.8% | Added |
| UBS Group AG | 1,746 | $2.55K | 0.00% | −4,567−72.3% | Reduced |
| Cornerstone National Bank & Trust Co | 1,428 | $2.08K | 0.00% | 00.0% | Unchanged |
| Trifecta Capital Advisors, LLC | 714 | $1.04K | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 571 | $834 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 357 | $521 | 0.00% | +357 | New |
| Morgan Stanley | 109 | $159 | 0.00% | 00.0% | Unchanged |
| Salem Investment Counselors Inc | 100 | $146 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 93 | $136 | 0.00% | −633,939−100.0% | Reduced |
| MAI Capital Management | 71 | $104 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 22 | $32 | 0.00% | −3−12.0% | Reduced |
| SBI Securities Co., Ltd. | 3 | $4 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1 | $1 | 0.00% | 00.0% | Unchanged |